X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CRN00808 (paltusotine) is an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is being evaluated for the treatment of patients with non-pharmacologically treated acromegaly.
Lead Product(s): Paltusotine
Therapeutic Area: Endocrinology Product Name: CRN00808
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 19, 2024
Details:
Crinetics lead product candidate CRN00808 (paltusotine), an SST2 agonist. Currently, it is being evaluated in the Phase II clinical trial studies for the treatment of Carcinoid Syndrome.
Lead Product(s): Paltusotine
Therapeutic Area: Oncology Product Name: CRN00808
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 12, 2024
Details:
Crinetics intends to use the net proceeds from the private placement to fund research and development of its clinical-stage product CRN00808 (paltusotine) for the treatment of Acromegaly rare hormonal disorder.
Lead Product(s): Paltusotine
Therapeutic Area: Endocrinology Product Name: CRN00808
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Adage Capital Partners
Deal Size: $350.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement February 28, 2024
Details:
CRN-00808 (paltusotine) is the first oral, once-daily selectively-targeted somatostatin receptor type 2 (SST2) agonist and is currently in investigational Phase 3 studies for acromegaly and a Phase 2 study for carcinoid syndrome.
Lead Product(s): Paltusotine
Therapeutic Area: Oncology Product Name: CRN-00808
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2023
Details:
The proceeds will fund development of CRN00808 (paltusotine), a small molecule SST2 agonist, in Phase 3 for acromegaly and Phase 2 for carcinoid syndrome and CRN04894, a small molecule ACTH antagonist, in Phase 2 for Cushing’s disease and congenital adrenal hyperplasia.
Lead Product(s): Paltusotine
Therapeutic Area: Endocrinology Product Name: CRN00808
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $350.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 12, 2023
Details:
The proceeds will fund development of CRN00808 (paltusotine), a small molecule SST2 agonist, in Phase 3 for acromegaly and Phase 2 for carcinoid syndrome and CRN04894, a small molecule ACTH antagonist, in Phase 2 for Cushing’s disease and congenital adrenal hyperplasia.
Lead Product(s): Paltusotine
Therapeutic Area: Endocrinology Product Name: CRN00808
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $250.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 11, 2023
Details:
CRN00808 (paltusotine) is the first oral, once-daily selectively targeted somatostatin receptor type 2 (SST2) agonist and is currently in Phase 3 investigational studies for acromegaly.
Lead Product(s): Paltusotine
Therapeutic Area: Endocrinology Product Name: CRN00808
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 10, 2023
Details:
Under the partnership, Quotient will support Crinetics' CRN04894 pediatric program. The partnership will utilize Quotient Sciences' unique Translational Pharmaceutics® platform to provide integrated formulation development, clinical manufacturing, and taste assessment studies.
Lead Product(s): CRN04894
Therapeutic Area: Endocrinology Product Name: CRN04894
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Quotient Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 30, 2023
Details:
CRN04777, an investigational, oral somatostatin receptor type 5 (SST5) agonist being developed as a treatment for congenital hyperinsulinism, Results from the study from Phase 1 showed CRN04777 was well tolerated at doses from 30 mg to 120 mg.
Lead Product(s): CRN04777
Therapeutic Area: Genetic Disease Product Name: CRN04777
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 28, 2022
Details:
CRN04777 is a highly optimized, orally available, small molecule somatostatin receptor type 5 (SST5) selective agonist that is designed to reduce the excess secretion of insulin in patients with congenital monogenic and syndromic HI, and other conditions of excess insulin.
Lead Product(s): CRN04777
Therapeutic Area: Genetic Disease Product Name: CRN04777
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
